BNY Mellon Appointed as Depositary Bank by Hadasit Bio-Holdings, Ltd.

NEW YORK, June 20, 2011 -

BNY Mellon, the global leader in investment management and
investment services, has been selected by Hadasit Bio-Holdings,
Ltd. (HBL) as depositary bank for its American depositary receipt
(ADR) program.  Each HBL ADR represents 20 ordinary shares and
trades on the over-the-counter (OTC) market under the symbol
“HADSY.”  HBL’s ordinary shares trade on the Tel Aviv Stock
Exchange under the symbol HDST.

HBL manages a portfolio of companies based on intellectual
property generated by Israel’s foremost medical research center -
Hadassah University Hospital - which is responsible for the
majority of Israel’s hospital-based translational research.
 All of the portfolio companies are based on inventions
developed and owned by Hadassah.  The companies operate in the
fields of oncology (therapeutics and diagnostics), regenerative
medicine, and inflammatory disease.  HBL focuses on funding
the portfolio companies’ preparation for and execution of Phase I
and preparation for Phase II.  Preparations include
pre-clinical trials, manufacturing, regulatory and business
development tasks.  

“Israel is known as a ’start-up nation,’ and we are very excited
to give investors access to a promising group of Israeli BioMed
startups through HBL,” said Ophir Shahaf, chief executive officer
of HBL - Hadasit Bio-Holdings.  ”With BNY Mellon’s superb
depositary receipts team supporting our efforts, we are confident
to make the most of our ADR and the possibilities for global
exposure it creates.”

“Israel’s strength in the bio-pharmaceutical fields is world
renowned, and HBL has a compelling story within that space,” said
Michael Cole-Fontayn, chief executive officer of BNY Mellon’s
Depositary Receipts business.  ”HBL has strong global
connections through Hadassah, and we will work together to maximize
exposure for its newly-created ADR through an array of investor
relations and visibility initiatives.”

BNY Mellon acts as depositary for more than 2,100 American and
global depositary receipt programs, acting in partnership with
leading companies from 67 countries. With an unrivaled commitment
to helping securities issuers succeed in the world’s rapidly
evolving financial markets, the company delivers the industry’s
most comprehensive suite of integrated depositary receipt,
corporate trust and stock transfer services. Learn more at href="www.bnymellon.com/dr">www.bnymellon.com/dr.

BNY Mellon is a global financial services company focused on
helping clients manage and service their financial assets,
operating in 36 countries and serving more than 100 markets.
 BNY Mellon is a leading provider of financial services for
institutions, corporations and high-net-worth individuals, offering
superior investment management and investment services through a
worldwide client-focused team.  It has $25.5 trillion in
assets under custody and administration and $1.2 trillion in assets
under management, services $11.9 trillion in outstanding debt and
processes global payments averaging $1.7 trillion per day.
 BNY Mellon is the corporate brand of The Bank of New York
Mellon Corporation (NYSE: BK). Learn more at href="www.bnymellon.com/">www.bnymellon.com.

This release is for informational purposes only. BNY Mellon
provides no advice nor recommendation or endorsement with respect
to any company or securities. Nothing herein shall be deemed to
constitute an offer to sell or a solicitation of an offer to buy
securities. Depositary Receipts: Not FDIC, State or Federal Agency
Insured; May Lose Value; No Bank, State or Federal Agency
Guarantee.

Joseph F. Ailinger Jr., +1-617-722-7571, joe.ailinger at bnymellon.com, or Dori Flanagan, +1-212-815-2291, dori.flanagan at bnymellon.com